Vera Therapeutics, Inc.· VERA

🇺🇸 US · MidBroad USNASDAQ

HealthcareBiotechnologyWebsite

Price: $29.95
Day: -7.07%
Mkt Cap: $2.15B
52W Range: $19.07 – $56.05
Volume: 4.91M
Beta: 0.95

D25D FrameworkTTM Data

Peer Comparison

Performance vs sector and industry peers across 40 metrics.

Blog

stockoscope.com

Vera Therapeutics, Inc.

VERA|Healthcare|Biotechnology

Comparing against 140 sector peers in United States · Mid Cap · Healthcare

Peer Comparison

Dimension 2 of 5

Revenue Growth

N/A

Operating Margin

36%ile

0.0%

ROIC

N/A

FCF Yield

1%ile

-13.7%

Growth & Cash Flow Quality

Percentile ranking across profitability growth and cash generation

EBITDA Growth

114.4%

EBIT Growth

113.0%

Net Income Growth

110.3%

OCF Growth

88.8%

FCF Growth

62.1%

Income Quality

0.79

Returns on Capital (TTM)

ROE(N/A)

N/A

PoorWeakAdequateStrongExceptional

ROCE(N/A)

N/A

PoorWeakAdequateStrongExceptional

ROA(N/A)

N/A

PoorWeakAdequateStrongExceptional

ROIC(N/A)

N/A

PoorWeakAdequateStrongExceptional

Profit Margins (TTM)

Gross Margin(0.0%)

14%ile

Bottom 20%

PoorWeakAdequateStrongExceptional

EBITDA Margin(0.0%)

31%ile

Below Avg

PoorWeakAdequateStrongExceptional

Operating Margin(0.0%)

36%ile

Below Avg

PoorWeakAdequateStrongExceptional

Net Margin(0.0%)

44%ile

Average

PoorWeakAdequateStrongExceptional

Leverage & Coverage (TTM)

Debt/Equity

52%ile

0.15

Debt/Capital

51%ile

0.13

Net Debt/EBITDA

92%ile

0.11

Interest Coverage

23%ile

-33.98x

Liquidity (TTM)

Current Ratio

78%ile

13.6

Quick Ratio

78%ile

13.6

Cash Ratio

66%ile

2.53

WC Turnover

12%ile

0.00

Operational Efficiency (TTM)

Asset Turnover

N/A

DSO

85%ile

0.00

Days Inventory

74%ile

0.00

Cash Conv. Cycle

N/A

TTM: Trailing Twelve Months · EBITDA: Earnings Before Interest, Taxes, Depreciation & Amortization · EBIT: Earnings Before Interest & Taxes · ROA: Return on Assets · ROIC: Return on Invested Capital · ROCE: Return on Capital Employed · ROE: Return on Equity · OCF: Operating Cash Flow · FCF: Free Cash Flow · DSO: Days Sales Outstanding · WC: Working Capital

See the complete picture

The full 5D Framework: Business Quality · Peer Comparison · Valuation · Analyst Sentiment · Smart Money

Explore VERA on stockoscope.com→

Generated August 5, 2026

For educational purposes only. Not financial advice. Data may be delayed or incomplete.

140 sector peers (United States · Mid Cap · Healthcare)

Relative Quality

VERA Relative Quality Score

Ranked against 140 sector peers in United States · Mid Cap · Healthcare

Relative Quality

3.5/5

Strong

vs 140 sector peers

Peer Rankings (7 of 10 available)

Relative Quality Score of 3.53/5 (Strong) based on percentile rankings against 140 sector peers in United States · Mid Cap · Healthcare. Each pillar shows a 1-5 score plus the cohort percentile (e.g. 95p = top 5%); higher percentiles indicate stronger relative performance.Last updated August 5, 2026.

Top-Line and Profit Growth

How does the company's growth rate compare to peers?

No data for Revenue Growth is available for VERA, so peer comparison is hidden for this metric. Try another metric.

Margin Efficiency

Does the company maintain better profit margins than peers?

Gross Margin

14th percentile, Poor

Value: 0.00%
Percentile: 14%
Score: 1/5

PoorWeakAdequateStrongExceptional

Analysis

VERA has a ttm gross margin of 0.00% and ranks at the 14th percentile vs United States · Healthcare sector peers. Poor financial performance.

Operational Efficiency

Is the company more operationally efficient than competitors?

No data for Asset Turnover is available for VERA, so peer comparison is hidden for this metric. Try another metric.

Returns Overview

Does the company generate better returns on capital than peers?

No data for ROA is available for VERA, so peer comparison is hidden for this metric. Try another metric.

Cash Flow Quality

How does the company's cash generation compare to peers?

Operating Cash Flow Growth

89th percentile, Exceptional

Value: 88.85%
Percentile: 89%
Score: 5/5

PoorWeakAdequateStrongExceptional

Analysis

VERA has a ttm operating cash flow growth of 88.85% and ranks at the 89th percentile vs United States · Healthcare sector peers. Top-tier financial performance.

Liquidity and Working Capital

Does the company maintain better liquidity positions than competitors?

Cash Ratio

66th percentile, Strong

Value: 2.53
Percentile: 66%
Score: 4/5

PoorWeakAdequateStrongExceptional

Analysis

VERA has a ttm cash ratio of 2.53 and ranks at the 66th percentile vs United States · Healthcare sector peers. Strong financial performance.

Leverage and Coverage

Is the company's debt burden more manageable than peers?

Debt to Capital

51st percentile, Adequate

Value: 0.13
Percentile: 51%
Score: 3/5

PoorWeakAdequateStrongExceptional

Analysis

VERA has a ttm debt-to-capital of 0.13 and ranks at the 51st percentile vs United States · Healthcare sector peers. Adequate financial performance.

Valuation Multiples

Is the company's stock valuation attractive relative to peers?

P / E Ratio

Insufficient peer data

Value: -5.41
Percentile: n/a
Score: n/a

PoorWeakAdequateStrongExceptional

Analysis

Not enough peer data to rank VERA for ttm p/e ratio in this cohort.

Dividend and Shareholder Yield

Does the company deliver superior income to shareholders compared to peers?

No data for Dividend Yield is available for VERA, so peer comparison is hidden for this metric. Try another metric.

Peer companies

The 140 companies VERA is compared against across its sector and industry cohorts.

Vera Therapeutics, Inc.· VERA

Peer Comparison

Top-Line and Profit Growth

Per-Share Fundamentals

Margin Efficiency

Operational Efficiency

Returns Overview

Cash Flow Quality

Liquidity and Working Capital

Leverage and Coverage

Valuation Multiples

Dividend and Shareholder Yield

Peer companies

Search stocks

Peer Comparison

Top-Line and Profit Growth

Per-Share Fundamentals

Margin Efficiency

Operational Efficiency

Returns Overview

Cash Flow Quality

Liquidity and Working Capital

Leverage and Coverage

Valuation Multiples

Dividend and Shareholder Yield

Peer companies